Evidence map›Paper›PMID 42402591›Full record

Observational studyPediatric rheumatology online journal2026

Critical care outcomes of hemophagocytic lymphohistiocytosis in children: a single centre retrospective observational study.

Manuel Murciano, Gabriella Bottari, Denise Pires Marafon, Francesca De Luca, Fabrizio Chiusolo, Pietro Merli, Corrado Cecchetti, Fabrizio De Benedetti, Matteo Di Nardo, Claudia Bracaglia

Abstract readObservational Study
In one paragraph

Observational study in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manuel MurcianoDepartment of Emergency and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, 00165, Rome, Italy.
Gabriella BottariDepartment of Emergency and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, 00165, Rome, Italy. gabriella.bottari@opbg.net.
Denise Pires MarafonDivision of Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesca De LucaDepartment of Maternal Sciences, Sapienza University of Rome, Rome, Italy.
Fabrizio ChiusoloAnesthesia and Critical Care Medicine, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Pietro MerliDepartment of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Corrado CecchettiDepartment of Emergency and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, 00165, Rome, Italy.
Fabrizio De BenedettiDivision of Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Matteo Di NardoDepartment of Emergency and General Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio 4, 00165, Rome, Italy.
Claudia BracagliaDivision of Rheumatology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHemophagocytic lymphohistiocytosis (HLH) is a challenging and potentially life-threatening condition characterized by an uncontrolled inflammatory response resulting from hyperactivation of T lymphocytes and macrophages, leading to excessive production of inflammatory cytokines. HLH can lead to multiple organ failure and death in a significant proportion of cases. It is challenging to differentiate HLH from sepsis. This study aims to describe the clinical characteristics, risk factors, and outcomes of a cohort of children admitted to a pediatric intensive care unit (PICU) with primary and secondary hemophagocytic lymphohistiocytosis (pHLH and sHLH).

methodsRetrospective observational analysis of all children with HLH admitted to the PICU between 2006 and 2019.

resultsPatients were evaluated at two time points: upon PICU admission (T1) and at the time of the highest ferritin level (T2). A total of 48 patients were included: 5 with pHLH, 37 with sHLH, and 6 with macrophage activation syndrome (MAS) in the context of systemic juvenile idiopathic arthritis (sJIA). The overall mortality rate in the PICU was 33.3%. Mortality rates within each group were: 60% for pHLH, 35.1% for sHLH, and nobody for MAS. The Pediatric Index of Mortality (PIM2) was higher among non-survivors. Splenomegaly and leukopenia at PICU admission were more common in non-survivors compared to survivors, as were the incidence of multiple organ failure and acute renal failure during the PICU stay. Platelet counts were significantly lower in patients who died, but only at T2. Ferritin levels remained consistently elevated in non-survivors throughout their PICU stay.

conclusionsIn this cohort, mortality among children admitted to the PICU with HLH was high, particularly among those with primary or onco-hematological forms. Conversely, patients with MAS experienced more relapses but no mortality was observed in this sample. Early presence of splenomegaly, low platelet count, elevated ferritin levels, and PIM2 score at PICU admission appear to be indicators of poor prognosis. These findings may help to early identify patients at highest risk for complications and mortality.

Indexed as

Critical CareLymphohistiocytosis, HemophagocyticAdolescentChildChild, PreschoolFemaleFerritinsHumansInfantIntensive Care Units, PediatricMacrophage Activation SyndromeMaleMultiple Organ FailureRetrospective StudiesRisk FactorsFerritinsExtracorporeal supportHemophagocytic lymphohistiocytosisHLHInflammationMacrophage activation syndromeMASMortalityOrgan failurePediatric intensive carePICU

Identifiers

PMID42402591
PMCPMC13617822

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.